Structure- and ligand-based drug design of novel p38-alpha MAPK inhibitors in the fight against the Alzheimers disease

Journal of Biomolecular Structure and Dynamics

Volumn 32, Issue 7, 2014, Pages 1047-1063

  Pinsetta, Flávio Roberto ^a   Taft, Carlton Anthony ^b   De Paula Da Silva, Carlos Henrique Tomich ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CENTRO BRASILEIRO DE PESQUISAS FÍSICAS   (Brazil)

Author keywords

Alzheimer's disease; drug design; p38 alpha MAPK

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE INHIBITOR;

ALZHEIMER DISEASE; ARTICLE; CARCINOGENICITY; DRUG ABSORPTION; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG METABOLISM; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME CONFORMATION; HUMAN; LIGAND BINDING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MUTAGENICITY; PHOTOALLERGY; PHOTOTOXICITY; PHYSICAL CHEMISTRY; PREDICTION; PRIORITY JOURNAL; SKIN SENSITIZATION; STATIC ELECTRICITY; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; CHEMICAL DATABASE; CHEMISTRY; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; DATABASES, CHEMICAL; DRUG DESIGN; LIGANDS; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN KINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84899969869     PISSN: 07391102     EISSN: 15380254     Source Type: Journal    
DOI: 10.1080/07391102.2013.803441     Document Type: Article

References (69)

1. Allen F. H. (2002). The Cambridge Structural Database: A quarter of a million crystal structures and rising. Acta Crystallographica. Section B Structural Science 58 380-388.
2. Alonso H. Bliznyuk A. A. & Gready J. E. (2006). Combining docking and molecular dynamic simulations in drug design. Medicinal Research Reviews 26 531-568.
3. Banerjee A. Koziol-White C. & Panettieri R. Jr. (2012). p38 MAPK inhibitors IKK2 inhibitors and TNF inhibitors in COPD. Current Opinion in Pharmacology 12 287-292.
4. Benfenati E. Gini G. 1997 Computational predictive programs (expert systems) in toxicology Toxicology 119 213-225.
5. Berchtold N. C. & Cotman C. W. (1998). Evolution in the conceptualization of dementia and Alzheimer's disease: Disease. Neurobiology of Aging 19 173-189.
6. Berman H. M. Westbrook J. Feng Z. Gilliland G. Bhat T. N. Weissig H. Shindyalov I.N. & Bourne P. E. (2000). The Protein Data Bank. Nucleic Acids Research 28 235-242.
7. Boström J. Greenwood J. R. & Gottfries J. (2003). Assessing the performance of OMEGA with respect to retrieving bioactive conformations. Journal of Molecular Graphics and Modelling 21 449-462.
8. Brooijmans N. & Kuntz I. D. (2003). Molecular recognition and docking algorithms. Annual Review of Biophysics and Biomolecular Structure 32 335-373.
9. Chico L. K. Van Eldik L. J. & Watterson D. M. (2009). Targeting protein kinases in central nervous system disorders. Nature Reviews Drug Discovery 8 892-909.
10. Citron M. (2004). [beta]-Secretase inhibition for the treatment of Alzheimer's disease-promise and challenge. Trends in Pharmacological Sciences 25 92-97.
11. Cole S.L. & Vassar R. (2007). The Alzheimer's disease betasecretase Enzyme BACE1. Molecular Neurodegeneration 2 22-32.
12. Dalrymple S. A. (2002). P38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease. Journal of Molecular Neuroscience 19 295-304.
13. DEREK10.0. 2004. Leeds: LHASA Limited.
14. Discovery Studio. (2012) Versao 3.5. San Diego CA: Accelrys Inc.
15. Dvir H. Jiang H. L. Wong D. M. Harel M. Chetrit M. He X. C. Sussman J. L. (2002). X-ray structures of Torpedo californica acetylcholinesterase complexed with (+)-huperzine A and (-)-huperzine B: structural e vidence for an active site rearrangement. Biochemistry 41 10810-10818.
16. Eldridge M. D. Murray C. W. Auton T. R. Paolini G. V. & Mee R. P. (1997). Empirical scoring functions: I. The develop ment of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. Journal of Computer-Aided Molecular Design 11 425-445.
17. EON. (2007). Versao 2.0.1. Santa Fe NM: Openeyes Scientific Software.
18. Giacobini E. (1998). Cholinergic foundations of Alzheimer's disease therapy. Journal of Physiology-Paris 92 283-290.
19. GLIDE. (2009). Versao 5.5. New York NY: Schrödinger LLC.
20. GOLD. (2009). Versao 5.1. Cambridge: Cambridge Crystallographic Datacenter.
21. Gompel M. Leost M. De Kier Joffe E. B. Puricelli L. Franco L. H. Palermo J. & Meijer L. 2004). Meridianins a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. Bioorganic & Medicinal Chemistry Letters 14 1703-1710.
22. Goodford P. J. (1985). A computat ional procedure for determining energetically favorable binding sites on biologically important macromolecules. Journal of Medicinal Chemistry 28 849-857.
23. Grant J. A. Gallardo M. A. & Pickup B. T. (1996). A fast method of molecular shape comparison: A simple application of a Gaussian description of molecular shape. Journal of Computational Chemistry 17 1653-1666.
24. Grant J. A. Pickup B. T. Sykes M. J. Kitchen C. A. & Nicholls A. (2007). A simple formula for dielectric polarisation energies: The Sheffield Solvation Model. Chemical Physics Letters 44 163-166.
25. GRID. (2006). Versao 22. London: Molecular Discovery Ltd.
26. Guex N. & Peitsch M. C. (1997). SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling. Electrophoresis 18 2714-2723.
27. Haigh J. A. Pickup B. T. Grant J. A. Nicholls A. 2005 Small molecule shape-fingerprints Journal of Chemical Information and Modeling 45 673-684.
28. Halperin I. Ma B. Wolfson H. & Nussinov R. (2002). Principles of docking: An overview of search algorithms and a guide to scoring functions. Proteins 47 409-443.
29. Heinig M. & Frishman D. (2004). STRIDE: A web server for secondary structure assignment from known atomic coordinates of proteins. Nucleic Acids Research 32(Web Server issue) W500-2.
30. Hert J. Willett P. Wilton D. J. Acklin P. Azzaoui K. Jacoby E. & Schuffenhauer A. (2004). Comparison of fingerprint-based methods for virtual screening using multiple bioactive reference structures. Journal of Chemical Information and Computer Sciences 44 1177-1185.
31. Insight II. (2000). Molecula r simulations. San Diego CA.
32. Irwin J. J. Sterling T. Mysinger M. M. Bolstad E. S. & Coleman R. G. (2005). ZINC: A free tool to discover chemistry for biology. Journal of Chemical Information and Modeling.
33. Irwin J. J. & Shoichet B. K. (2005). ZINC-A free database of commercially available compounds for virtual screening. Journal of Chemical Information and Modeling 45 177-182.
34. Johnson G. V. & Bailey C. D. (2003). The p38 MAP kinase signaling pathway in Alzheimer's disease. Experimental Neurology 183 263-271.
35. Kirchmair J. Wolber G. Laggner C. & Langer T. (2006). Comparative performance assessment of the conformational model generators omega and catalyst: A large-scale survey on the retrieval of protein-bound ligand conformations. Journal of Chemical Information and Modeling 46 1848-1861.
36. Koes D. R. & Camacho C. J. (2012). ZINCPharmer: Pharmacophore search of the ZINC database. Nucleic Acids Research 40(Web Server issue) W409-W414.
37. Kuglstatter A. Stahl M. Peters J. U. Huber W. Stihle M. Schlatte D. Hennig M. (2008). Tyramine fragment binding to BACE-1. Bioorganic & Medicinal Chemistry Letters 18 1304-1311.
38. Kumar A. & G hosh I. (2007). Mapping selectivity and specificity of active site of plasmepsins from Plasmodium falciparum using molecular interaction field approach. Protein and Peptide Letters 14 569-574.
39. Kuret J. Johnson G. S. Cha D. Christenson E. R. DeMaggio A. J. & Hoekstra M. F. (1997). Casein kinase 1 is tightly associated with paired-helical filaments isolated from Alzheimer's disease brain. J ournal of Neurochemistry 69 2506-2521.
40. Laurie A. T. & Jackson R. M. (2005). Q-SiteFinder: An energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 21 1908-1916.
41. Lee M. R. & Dominguez C. (2005). MAP Kinase p38Inhibitors: Clinical results and an intimate look at their interactions with p38 protein. Current Medicinal Chemistry 12 2979-2994.
42. Lengauer T. (2002). Bioinformatics: From genomes to drugs. Methods and principles in medicinal chemistry (Vol. 1). Weinheim: Wiley-VHC Verlag.
43. Liu X. Ouyang S. Yu B. Liu Y. Huang K. Gong J. Jiang H. (2010). PharmMapper server: A web server for potential drug target identification using pharmacophore mapping approach. Nucleic Acids Research 38 W609-14.
44. Lu Q. Wang C. Pan R. G ao X. Wei Z. Xia Y. & Dai Y. (2013). Histamine synergistically promotes bFGF-induced angiogenesis by enhancing VEGF production via H1 receptor. Journal of Cellular Biochemistry 114 1009-1019.
45. M artin K. J. & Arthur J. S. (2012). Selective kinase inhibitors as tools for neuroscience research. Neuropharmacology 63 1227-1237.
46. Matos K. S. da Cunha E. F. da Silva Gonçalves A Wilter A. Kua K. Franç a T. C. & Ramalho T. C. (2012). First principles calculations of thermodynamics and kinetic parameters and molecular dynamics simulations of acetylcholinesterase reactivators: Can mouse data provide new insights into humans Journal of Biomolecular Structure & Dynamics 30 546-558.
47. Mohan C. G. Gandhi T. Garg D. & Shinde R. (2007). Computer-assisted methods in chemical toxicity prediction. Mini Reviews in Medicinal Chemistry 7 499-507.
48. Mohan V. Gibbs A. C. Cummings M. D. Jaeger E. P. & DesJarlais R. L. (2005). Docking: Successes and challenges. Current Pharmaceutical Design 11 3233-3333.
49. Muchmore S. W. Souers A. J. Akritopoulou-Zanze I. 2006 The use of three-dimensional shape and electrostatic similarity searching in the identification of a melaninconcentrating hormone receptor 1 antagonist Chemical Biology & Drug De sign 67 174-176.
50. Mucke L. (2009). Neuroscience: Alzheimer's disease. Nature 461 895-902.
51. Muster W. Breidenbach A. Fischer H. Kirchner S. Müller L. & Pähle r A. (2008). Computational toxicology in drug development. Drug Discovery Today 13 303-310.
52. Nwaka S. & Hudson A. (2006). Innovative lead discovery strategies for tropical diseases. Nature Reviews Drug Discovery 5 941-955.
53. Omega. (2006). Versao 2.0. Santa Fe NM: Openeyes Scientific Software.
54. Perry J. J. Harris R. M. Moiani D. Olson A. J. & Tainer J. A. (2009). p38alpha MAP kinase C-terminal domain binding pocket characterized by crystallographic and computational analyses. Journal of Molecular Biology 391 1-11.
55. Pinsetta F. R. Taft C. A. & Silva C. H. T. P. (2013). Rational design of novel potential p38 MAPK inhibitors with drug-like properties using pharmacophore and similarity-based virtual screening procedures. Current Bioactive Compounds 13 3-13.
56. Polgar T. & Keseru G. M. (2005). Virtual screening for betasecretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. Journal of Medicinal Chemistry 48 3749-3755.
57. QikProp. (2011). V ersion 3.4. New York NY: Schrödinger LLC.
58. Reichman W. E. (2003). Current pharmacologic options for patients with Alzheimer's disease. Annals of General Hospital Psychiatry 2 1.
59. Schneidma n-Duhovny D. Dror O. Inbar Y. Nussinov R. & Wolfson H. J. (2008). PharmaGist: A webserver for ligandbased pharmacophore detection. Nucleic Acids Research 36 W223-W228.
60. Scior T. Bender A. Tresadern G. Medina-Franco J. L. Martí nez-Mayorga K. Langer T. Cuanalo-Contreras K. & Agrafiotis D. K. (2012). Recognizing pitfalls in virtual screening: A critical review. Journal of Chemical In formation and Modeling 52 867-881.
61. Shintani E. Y. & Uchida K. M. (1997). Donepezil: An anticholinesterase inhibitor for Alzheimer's disease. American Journal of Health-System Pharmacy 54 2805-2815.
62. Simard J. R. Grütter C. Pawar V. Aust B. Wolf A. Rabiller M. Rauh D. (2009). High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha. Journal of the American Chemical Society 131(51) 18478-18488.
63. Singh T. J. Grundke-Iqbal I. & Iqbal K. (1995). Phosphorylation of tau protein by casein kinase-1 converts it to an abnormal Alzheimer-like state. Journal of Neurochemistry 64 1420-1423.
64. Sutherland J. J. Nandigam R. K. Erickson J. A. & Vieth M. (2007). Lessons in molecular recognition. 2. Assessing and improving cross-docking accuracy. Journal of Chemical Information and Modeling 47 2293-2302.
65. T aft C. A. & Silva C. H. T. P. (2013). Comments on the paper Levinthal's question revisited and answered. Journal of Biomolecular Structure & Dynamics doi:10.1080/07391102.2012.748540. The PyMOL Molecular Graphics System Ve rsion 1.2r3pre Schrödinger LL.
66. Tuccinardi T. Ortore G. Santos M. A. Marques S. M. Nuti E. Rossello A. & Martinelli A. (2009). Multitemplate alignment method for the development of a reliab le 3DQSAR model for the analysis of MMP3 inhibitors. Journal of Chemical Information and Modeling 49 1715-1724.
67. Weiner M. W. (2012). Dementia in (2012) further insights into Alzheimer disease pathogenesis. Nature Reviews 9 65-66.
68. Yasuda S. Sugiura H. Tanaka H. Takigami S. & Yamagata K. (2011). p38 MAP kinase inhibitors as potential therapeutic drugs for neural diseases. Central Nervous System Agents in M edicinal Chemistry 11 45-59.
69. Zhang Y. Y. Mei Z. Q. Wu J. W. & Wang Z. X. (2008). Enzymatic activity and substrate specificity of mitogen-activated protein kinase p38alpha in different phosphoryl ation states. Journal of Biological Chemistry 283 26591-26601.